Genomic and epidemiologic analyses revealed that a novel reassortant viral lineage of the Oropouche virus, which has been circulating in the western Amazon region of Brazil for about a decade, is associated with the recent human outbreaks between 2022 and 2024.

In the observational SCRUM-Japan GOZILA study, after a median follow-up of 11 months, patients with metastatic gastrointestinal tumors who received biomarker-matched therapies based on circulating tumor DNA profiling showed a greater clinical benefit than those receiving unmatched therapy.

Studies in China show how large language models can improve primary healthcare systems, but equitably scaling this technology will require attention to rural, low-resource settings and the companion policies that support its implementation.

Senolytics can prevent and treat age-related diseases in mice, but data in humans are lacking — for now.

Genomic and epidemiologic analyses revealed that a novel reassortant viral lineage of the Oropouche virus, which has been circulating in the western Amazon region of Brazil for about a decade, is associated with the recent human outbreaks between 2022 and 2024.

Trained on a cohort of 45,064 cases and validated on data acquired from mobile computed tomography scanners deployed in rural China, a lung cancer screening deep learning model is shown to outperform existing lung cancer risk scores.

In a large cohort with a 23-month median follow-up of the CIRCULATE-Japan GALAXY observational study, ctDNA-based detection of molecular residual disease was predictive of survival outcomes and benefit of adjuvant chemotherapy in patients with resectable colorectal cancer.

In the phase 2 adaptive BELLINI trial, patients with early-stage triple-negative breast cancer received neoadjuvant nivolumab with or without ipilimumab, showing immune activation, clearance of circulating tumor DNA and promising clinical response rates, especially in patients preselected based on high levels of tumor-infiltrating lymphocytes.

In the observational SCRUM-Japan GOZILA study, after a median follow-up of 11 months, patients with metastatic gastrointestinal tumors who received biomarker-matched therapies based on circulating tumor DNA profiling showed a greater clinical benefit than those receiving unmatched therapy.

In the phase 2 NICHE-3 trial, patients with locally advanced mismatch repair-deficient colon cancer who were treated with neoadjuvant anti-PD1 and anti-LAG3 agents showed high rates of pathological responses, requiring validation in larger trials.

As drastically rising global temperatures threaten the health and wellbeing of populations, solutions that drive policy action must be based on scientific evidence of which strategies work in different scenarios.

Post-approval evidence generation is essential for high-quality clinical care and should be a shared priority for clinicians, health systems, payors, and the medical products industry, as well as the FDA and federal agencies.

In people undergoing medical abortion after 12 weeks of pregnancy, those who took the first dose of misoprostol at home were less likely to require overnight hospitalization.

The European Health Data Space provides an opportunity to benefit patients and the public.

Analysis of data related to the Ukraine famine of 1932–1933 shows that in utero exposure to famine increases the risk of adult type 2 diabetes by more than twofold.